Myristoylated alanine-rich C kinase substrate (MARCKS): A molecular target for the therapeutic action of mood stabilizers in the brain?

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 13, 1996, Pages 23-31

  Lenox, Robert H ^a   McNamara, Robert K ^a   Watterson, Jeannette M ^a   Watson, David G ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CARBAMAZEPINE; PHOSPHOTRANSFERASE; VALPROIC ACID;

CELL IMMORTALIZATION; CONFERENCE PAPER; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE TARGETING; HUMAN; HUMAN CELL; MYRISTYLATION; PRIORITY JOURNAL; PROPHYLAXIS; RECEPTOR DOWN REGULATION;

ANIMALS; BIPOLAR DISORDER; BLOTTING, WESTERN; CARBAMAZEPINE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GENE EXPRESSION; HIPPOCAMPUS; HUMANS; INOSITOL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LITHIUM CHLORIDE; MEMBRANE PROTEINS; NEURONS; PROTEIN BIOSYNTHESIS; PROTEIN KINASE C; PROTEINS; RABBITS; RATS; VALPROIC ACID;

EID: 0030454553     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
2. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) study. JAMA 1990;264:2511-2518
3. Lenox RH, Manji HK. Lithium. In: Nemeroff C, Schatzberg A, eds. APA Textbook of Psychopharmacology. Washington, DC: APA Press Inc; 1995: 303-349
4. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-1088
5. Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993;50:448-455
6. Post RM, Leverich GS, Altshuler L, et al. Lithium discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 1992;149: 1727-1729
7. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-924
8. Calabrese JR, Delucchi GA. Phenomenology of rapid cycling manic depression and its treatment with valproate. J Clin Psychiatry 1989:50(3, suppl):30-34
9. Calabrese JR, Markovitz PJ, Kimmel SE, et al. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992;12(suppl 1):53S-56S
10. Gerner RH, Stanton A. Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine? J Clin Psychopharmacol 1992;12(suppl 1):57S-63S
11. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 1992;12(suppl 1):42S-52S
12. Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991; 48:915-921
13. Bowden CL. Lithium comparison to valproate and carbamazepine. Presented at the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; June 23-27, 1996; Melbourne, Australia
14. Post RM, Weiss SRB, Chuang D-M. Mechanisms of action of anti-convulsants in affective disorders: comparisons with lithium. J Clin Psychopharmacol 1992;12(suppl 1):23S-35S
15. McElroy SL, Keck PE Jr, Stanton SP, et al. A randomized comparison of divaiproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57:142-146
16. Motohashi N. GABA receptor alterations after chronic lithium - in comparison with carbamazepine and sodium valproate. Clin Neuropharmacol 1990;13:207-208
17. Waldmeier PC. Is there a common denominator for the antimanic effect of lithium and antidepressants? Pharmacopsychiatry 1987;20:37-47
18. Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 1982;206:587-595
19. Godfrey PP. Potentiation by lithium of CMP-phosphatidate formation in carbachol-stimulated rat cerebral-cortical slices and its reversal by myoinositol. Biochem J 1989;258:621-624
20. Vadnal RE, Parthasarathy R. Myo-inositol monophosphatase: diverse effects of lithium, carbamazepine, and valproate. Neuropsychopharmacology 1995;12:277-285
21. Lenox RH. Role of receptor coupling to phosphoinositide metabolism in the therapeutic action of lithium. In: Ehrlich YH, Lenox RH, Kornecki E, et al, eds. Molecular Mechanisms of Neuronal Responsiveness. Adv. Exp. Biol. Med., vol 221. New York, NY: Plenum Press; 1987:515-530
22. Manji HK, Lenox RH. Long-term action of lithium, a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 1994;16:11-28
23. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995;9:484-496
24. Newton AC. Protein kinase C: structure, function and regulation. J Biol Chem 1995;270:28495-28498
25. Lenox RH, Watson DG, Patel J, et al. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992;570: 333-340
26. Aderem A. The MARCKS brothers: a family of protein kinase C substrates. Cell 1992;71:713-716
27. Blackshear PJ. The MARCKS family of cellular protein kinase C substrates. J Biol Chem 1993;268:1501-1504
28. Watson DG, Lenox RH. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J Neurochem 1996;67:767-777
29. Watson DG, Wainer BH, Lenox RH. Phorbol ester- and retinoic acid-induced regulation of the PKC substrate MARCKS in immortalized hippocampal cells. J Neurochem 1994;63:1566-1674
30. Seykora JT, Ravetch JV, Aderem A. Cloning and molecular characterization of the murine macrophage "68-kDa" protein kinase C substrate and its regulation by bacterial lipopolysaccharide. Proc Natl Acad Sci U S A 1991; 88:2505-2509
31. Lenox RH, Watson DG. Lithium and the brain, a psychopharmacological strategy to a molecular basis for manic-depressive illness. Clin Chem 1994; 40:309-314
32. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways: molecular targets for lithium's action. Arch Gen Psychiatry 1995;52:531-543
33. Ouimet CC, Wang JKT, Walaas SI, et al. Localization of the MARCKS (87 kDa) protein, a major specific substrate for the protein kinase C, in rat brain. J Neurosci 1990;10:1683-1698
34. McNamara RK, Watson DG, Lenox RH. Distribution of two primary protein kinase C (PKC) substrates, myristoylated alanine-rich C kinase substrate (MARCKS) and Fl/GAP-43 mRNAs, in the adult rat brain. Society for Neuroscience Abstracts 1995;21:2008
35. Gani D, Downes CP, Batty IH, et al. Lithium and myo-inositol homeostasis. Biochem Biophys Acta 1993;1177:253-269
36. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989;59:411-419
37. Li R, Wing LL, Wyatt RD, et al. Effects of haloperidol, lithium, and valproate on phosphoinositide turnover in rat brain. Pharm Biochem Behav 1993;46:323-329
38. Chen G, Manji HK, Hawver DB, et al. Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro. J Neurochem 1994;63:2361-2364
39. Manji HK, Etcheberrigaray R, Chen G, et al. Lithium decreases membrane-associated protein kinase C in hippocampus, selectivity for the α isozyme. J Neurochem 1993;61:2303-2310
40. Elphick M, Taghavi Z, Powell T, et al. Alteration of inositol phospholipid metabolism in rat cortex by lithium but not carbamazepine. Eur J Pharmacol 1988;156:411-414
41. Divish MM, Sheftel G, Boyle A, et al. Differential effect of lithium on fos protooncogene expression mediated by receptor and postreceptor activators of protein kinase C and cyclic adenosine monophosphate: model for its antimanic action. J Neurosci Res 1991;28:40-48